Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

  • Osorio J
  • Huang C
  • Kinney R
 et al. 
  • 89


    Mendeley users who have this article in their library.
  • 0


    Citations of this article.


Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated. © 2011 Elsevier Ltd.

Author-supplied keywords

  • DEN-2 PDK-53 virus
  • Dengue fever
  • Dengue virus
  • Recombinant viral vaccine
  • Vaccine development

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jorge E. Osorio

  • Claire Y H Huang

  • Richard M. Kinney

  • Dan T. Stinchcomb

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free